Learn Data For Researchers Find trials matched to me

Learn Data For Researchers Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Track your health while receiving bleeding disorder treatment | stella

Back to Hemophilia A trials

Recruiting

Safety study of a bleeding disorder treatment in routine care

Plain-English translation of NCT06222697 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Read our Hemophilia A research guide →

What is this trial?

This study is observing how safe damoctocog alfa pegol is when used in real-world medical practice for people with hemophilia A. Hemophilia A is a genetic bleeding disorder where the body doesn't make enough of a protein needed for blood to clot properly. Researchers will collect information from your routine clinic visits and medical records over about 8 months to make sure this medication is working safely for you.

Although this medication is already approved and in use, the company wants to gather more information about its safety when used in everyday medical practice in Korean patients. This helps doctors and patients have more confidence in the treatment and understand any side effects that might occur.

Do you qualify?

You likely qualify if…

you are at least 12 years old
you have been diagnosed with hemophilia A
you have previously received other hemophilia A treatments
you are currently being treated with damoctocog alfa pegol or your doctor has decided to start you on this medication
you are able to provide written informed consent (or a parent/guardian can consent for you)

You likely don't qualify if…

you are allergic to the medication or any of its components
you are currently enrolled in another research study that involves treatments outside of routine care
you have a bleeding or clotting disorder other than hemophilia A
you are currently undergoing immune tolerance induction treatment

What participation looks like

You will continue receiving your medication exactly as your doctor prescribes it—no changes to your treatment plan. The study simply involves collecting information from your regular clinic visits and medical records from December 2023 through March 2026. You won't need to do any extra visits or tests; researchers will only use the data from your routine care to track how safe and effective the treatment is for you over about 8 months.

AI-generated summary from trial data · Jul 2, 2026 · Not medical advice

Trial locations(1 site)

South Korea

Many Locations, Multiple Locations

Key details

Sponsor

Bayer

Enrollment target

~20 participants

Started

January 2024

Primary completion

March 2028

Age range

12 Years and older

Last updated on clinicaltrials.gov in June 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Bayer Clinical Trials Contact

Bayer

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov